AMRX (Amneal) Kelajakdagi narxning foydaga nisbati

Amneal (AMRX) kompaniyasining rasmiy ramzlari

Amneal Pharmaceuticals (AMRX) hamyonbop biosimilarlarining ishonchli yetkazib beruvchisi sifatidagi maqomini saqlab qolmoqda. Biroq, narxlardagi bosim va qarzlar uning manevr imkoniyatlarini cheklaydi, ekologik choralar esa rasmiy darajada qolmoqda. Kompaniyaning forward P/E baholashi bozor kutganlarini aks ettiradi, bunda 17.30 yakuniy daraja belgisi vazifasini o'taydi. Ushbu grafikning joriy tendentsiyasi tartibga soluvchi talablar sharoitidagi mahsulot realizatsiyasi darajalariga o'xshashdir.

amneal.com - AMRX Kapitalizatsiyaning kelajakdagi foydaga nisbati (davr: 04.07.2022 - 17.11.2026)

amneal.com (AMRX) boʻyicha maʼlumotlarning jamlanma tahliliy kesimlari

- joriy narx va aksiyalarning prognoz qilingan qiymati:
Fundamental baholash:Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals brendining mahsuloti

Himoya aktivlarini qidirish kelajakdagi daromadlar nisbatida past baholanganlikni aniqlashga asoslanadi, bu esa Amneal Pharmaceuticals (AMRX) va uning endokrinologiya hamda infeksiya terapiyasi uchun generic va patentlangan dori vositalari portfelining holati uchun juda muhimdir. Emitentning forward P/E ko'rsatkichini tahlil qilish orqali investor joriy aksiya narxini prognoz qilingan sof foyda prizmasidan baholaydi, bunda ko'rsatkichning pasayishi xavfsizlik zaxirasining oshishi yoki biznesning fundamental ko'rsatkichlarining tizimli ravishda yomonlashishidan dalolat beradi.

Raqobatdosh kompaniyalar tahlili

Kelajakdagi narxning foydaga nisbati haleon.com (HLN)|KVUE (Kenvue Health) - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Prognoz qilingan narx-foyda nisbati|LGND: Prognoz qilingan narxning foydaga nisbati|Perrigo - Kapitalizatsiyaning kelajakdagi foydaga nisbati|ALVO: Forvard P/E multiplikatori|Liquidia Technologies - Kelajakdagi narx-foyda multiplikatori|GLPG (Galapagos N.V.) - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati anipharmaceuticals.com ANIP|Kelajakdagi narxning foydaga nisbati MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Pacira BioSciences, Inc. PCRX|Forvard P/E multiplikatori ARS Corp SPRY|Theravance Biopharma - Forvard P/E multiplikatori|Forvard narx-foyda multiplikatori Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narxning foydaga nisbati Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati SXTC (China SXT Pharmaceuticals)|Forvard P/E multiplikatori EPRX|Forvard P/E multiplikatori bioharvest.com (BHST)|Kelajakdagi narxning foydaga nisbati Invizyne Technologies EXOZ|ORMP: Narxning kelajakdagi foydaga nisbati|ENTX: Prognoz qilingan narxning foydaga nisbati|HYFT: Kelajakdagi narxning foydaga nisbati|ABVC BioPharma Inc. (ABVC) - Kelajakdagi narxning foydaga nisbati|cumberlandpharma.com (CPIX) - Forvard P/E multiplikatori|QNTM (Quantum BioPharma) - Forvard P/E multiplikatori|FGEN: Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori TELO|Forvard P/E multiplikatori Rani Therapeutics Holdings (RANI)|Forvard P/E multiplikatori SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Prognoz qilingan narx-foyda nisbati|LEXX - Kelajakdagi narxning foydaga nisbati|PULM (Pulmatrix) - Narxning kelajakdagi foydaga nisbati|Pheton Holdings Ltd (PTHL) - Kelajakdagi narxning foydaga nisbati|Aptorum - Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati LYRA|Prognoz qilingan narxning foydaga nisbati Impact BioMedical Inc (IBO)|Forvard P/E multiplikatori TNFA|YCBD: Narxning kutilayotgan foydaga nisbati|Kelajakdagi narxning foydaga nisbati PainReform PRFX|altamiratherapeutics.com (CYTO) - Prognoz qilingan narx-foyda nisbati|LIPO: Prognoz qilingan narxning foydaga nisbati|OPTN (optinose.com) - Narxning kelajakdagi foydaga nisbati|PIRS: Forvard P/E multiplikatori|PROC - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|PTPI (Petros Pharma) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati QLI|Forvard P/E multiplikatori SLRN|Kapitalizatsiyaning kelajakdagi foydaga nisbati TFFP